Purpose To quantify the influence of common cytochrome P450 2C9 (CYP2C9)
polymorphisms on warfarin dose requirements. Methods A systematic review and a meta …

Background Warfarin is a highly effective anticoagulant however its effectiveness relies on
maintaining INR in therapeutic range. Finding the correct dose is difficult due to large inter …

Human cytochrome P450 2C9 (CYP2C9) accounts for∼ 20% of hepatic total CYP content
and metabolizes∼ 15% clinical drugs such as phenytoin, S-warfarin, tolbutamide, losartan …

We have identified an alternative pathway of tumorigenesis in sporadic colon cancer,
involving microsatellite instability due to mismatched repair methylation, which may be …

Cytochrome P450 2C19 (CYP2C19) is a member of the cytochrome P-450 enzyme
superfamily and plays an important role in the metabolism of drugs. In order to gain insights …

The biomedical research sector in Saudi Arabia has recently received special attention from
the government, which is currently supporting research aimed at improving the …

Warfarin is an oral anticoagulant frequently used in the treatment of different cardiovascular
diseases. Genetic polymorphisms in the CYP2C9 and VKORC1 genes have produced …

Background: Warfarin is the most commonly prescribed oral anticoagulant drug for
prophylaxis and treatment of venous and arterial thromboembolic disorders. Its …

Polymorphisms in the genes encoding CYP2C9 enzyme and VKORC1 reductase
significantly influence the dose variability of coumarinic oral anticoagulants (COAs) …

Background Warfarin is the mainstay of anticoagulation therapy worldwide. CYP2C9 and
VKORC1 are two major genetic factors associated with inter-individual and inter-ethnic …